id: NEW:caffeinated_coffee_consumption_to_cardiovascular_disease_mortality
name: Caffeinated Coffee Consumption â†’ Cardiovascular Disease Mortality
from_node:
  node_id: NEW:caffeinated_coffee_consumption
  node_name: Caffeinated Coffee Consumption
to_node:
  node_id: cardiovascular_disease_mortality
  node_name: Cardiovascular Disease Mortality
direction: negative
category: behavioral
mechanism_pathway:
- 'Step 1: Regular caffeinated coffee consumption delivers bioactive compounds including
  chlorogenic acids, caffeine, and other polyphenols to the body'
- 'Step 2: These compounds exert antioxidant and anti-inflammatory effects, reducing
  oxidative stress and chronic inflammation in vascular tissues'
- 'Step 3: Coffee bioactives improve endothelial function, reduce arterial stiffness,
  and modulate lipid metabolism favorably'
- 'Step 4: These cardiovascular protective effects lead to reduced atherosclerosis
  progression and lower risk of cardiovascular events'
- 'Step 5: The cumulative protective effects result in decreased cardiovascular disease
  mortality, with optimal benefit observed at 3-4 cups per day'
evidence:
  quality_rating: A
  n_studies: 26
  primary_citation: 'Matteo Di Maso et al. 2021. Caffeinated Coffee Consumption and
    Health Outcomes in the US Population: A Dose-Response Meta-Analysis and Estimation
    of Disease Cases and Deaths Avoided. Advances in Nutrition.'
  supporting_citations: []
description: 'Caffeinated coffee consumption is inversely associated with cardiovascular
  disease mortality. A meta-analysis of 26 prospective studies with over 3.7 million
  participants found that any coffee consumption compared to no consumption was associated
  with a 10% reduction in CVD risk (RR = 0.90, 95% CI: 0.84-0.96). The relationship
  follows a nonlinear dose-response pattern, with optimal protective effects observed
  at 3-4 cups per day. Current US consumption patterns would account for approximately
  6-12% of avoided cardiovascular deaths.'
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 0.9
    type: relative_risk
    ci_lower: 0.84
    ci_upper: 0.96
  p_value: null
  sample_size: 3713932
moderators:
- name: cups_per_day
  direction: u_shaped
  strength: moderate
  description: Dose-response relationship is nonlinear for CVD (P-nonlinearity = 0.01),
    with largest risk reduction at 3-4 cups/day (~120 mL/cup) and no additional reduction
    thereafter
